JK-P3

JK-P3 is a potent and pan VEGFR2 inhibitor, with IC50s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively. JK-P3 can inhibit VEGF-A-stimulated VEGFR2 activation and intracellular signalling, also inhibits endothelial monolayer wound closure and angiogenesis, as well as fibroblast growth factor receptor kinase activity in vitro. JK-P3 has anti-angiogenic activity[1].

Product Specifications

CAS Number

[942655-44-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

FGFR; VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/jk-p3.html

Purity

99.75

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=NNC(C2=CC=CC=C2)=C1)C3=CC=C(OC)C(OC)=C3

Molecular Formula

C18H17N3O3

Molecular Weight

323.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Kankanala J, et al. A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis. Br J Pharmacol. 2012;166 (2) :737-748.